PDB20 BIPHASIC INSULIN ASPART 30 VERSUS ORAL HYPOGLYCEMIC AGENTS IN THE TREATMENT OF TYPE-2 DIABETES- LONG-TERM PROJECTION OF CLINICAL AND COST OUTCOMES IN SWEDEN
Abstract
Authors
AJ Palmer M Lammert WJ Valentine JA Ray AS Brandt S Roze